Short answer
Amgen (AMGN) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). David W. Gibbs appointed director effective October 26, 2026, expanding the Board to 13 directors.
Amgen 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- David W. Gibbs appointed director effective October 26, 2026, expanding the Board to 13 directors
- Board remains highly independent: 12 of 13 directors independent
- Gibbs joins Audit and Compensation and Management Development committees
- Standard compensation includes $115,000 annual cash retainer and $12,500 committee retainer, prorated for 2026
- Pro-rated 7/12 equity award based on the $220,000 annual restricted-stock-unit grant; no related-party transactions disclosed
Item EX-99.1 · Exhibit EX-99.1
- David W. Gibbs appointed immediately to Amgen’s Board, expanding oversight and consumer-brand expertise
- Gibbs joins Audit Committee and Compensation and Management Development Committee
- Board expands to 13 directors, with 12 independent members
- Former Yum! Brands CEO from 2020 to 2025, offering experience in digital transformation and global customer engagement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amgen 8-K filings
Get the next AMGN 8-K as it lands
Follow AMGN for push alerts, or ask the research agent what this filing means.